Brokerages Set ICU Medical, Inc. (NASDAQ:ICUI) PT at $177.25

ICU Medical, Inc. (NASDAQ:ICUI) has received an average recommendation of “Moderate Buy” from the four research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $199.67.

A number of equities analysts have issued reports on the stock. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. KeyCorp lifted their price target on shares of ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. Jefferies Financial Group upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target for the company in a report on Wednesday, December 11th. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Raymond James lifted their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th.

Insider Activity at ICU Medical

In related news, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $162.91, for a total value of $1,954,920.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $17,039,245.63. The trade was a 10.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David C. Greenberg sold 972 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $158.11, for a total transaction of $153,682.92. Following the completion of the sale, the director now owns 5,037 shares of the company’s stock, valued at approximately $796,400.07. The trade was a 16.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 40,364 shares of company stock worth $6,869,878. 6.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On ICU Medical

Several institutional investors have recently bought and sold shares of ICUI. CWM LLC grew its stake in ICU Medical by 18.5% during the second quarter. CWM LLC now owns 767 shares of the medical instruments supplier’s stock worth $91,000 after buying an additional 120 shares during the period. SG Americas Securities LLC grew its stake in ICU Medical by 441.7% during the second quarter. SG Americas Securities LLC now owns 5,818 shares of the medical instruments supplier’s stock worth $691,000 after buying an additional 4,744 shares during the period. Blue Trust Inc. grew its stake in ICU Medical by 384.4% during the second quarter. Blue Trust Inc. now owns 1,090 shares of the medical instruments supplier’s stock worth $129,000 after buying an additional 865 shares during the period. Nisa Investment Advisors LLC grew its stake in ICU Medical by 3.2% during the second quarter. Nisa Investment Advisors LLC now owns 10,939 shares of the medical instruments supplier’s stock worth $1,299,000 after buying an additional 339 shares during the period. Finally, Kirr Marbach & Co. LLC IN grew its stake in ICU Medical by 5.6% during the second quarter. Kirr Marbach & Co. LLC IN now owns 23,809 shares of the medical instruments supplier’s stock worth $2,827,000 after buying an additional 1,269 shares during the period. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

ICU Medical Stock Performance

Shares of ICUI opened at $157.17 on Friday. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The stock has a market cap of $3.85 billion, a P/E ratio of -34.39 and a beta of 0.62. The company has a 50-day moving average of $170.34 and a two-hundred day moving average of $152.40. ICU Medical has a 12-month low of $86.80 and a 12-month high of $196.26.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.